Under the terms of the agreements, if INTERCEPT plasma is approved by the FDA, Cerus would provide INTERCEPT kits to BSI and the Red Cross and recoup the kit price from the final sale of the INTERCEPT plasma products. Collection and preparation of the INTERCEPT plasma would be performed by BSI and the Red Cross.
“The Red Cross and Blood Systems are two of the world’s preeminent blood centers, together producing approximately 60 percent of the US blood supply,” said William ‘Obi’ Greenman, Cerus’ president and CEO. “With the support of these two great partners in addition to this new business model for commercializing INTERCEPT treated blood components, we believe that we are well positioned for a successful US launch pending FDA approval of the INTERCEPT plasma system.”
In 2004, Cerus completed a phase 3 study of 35 TTP patients in which more than 3,500 units of INTERCEPT plasma were transfused. The primary endpoint of the trial, comparing the proportion of patients in the test and control groups achieving remission within 30 days after the first therapeutic plasma exchange, was met (82% of test patients achieving remission vs. 89% of patients in the control group). All secondary efficacy endpoints, comparing time to first remission, relapse rates and plasma exchange volume, were also met. The results of this study were published in the journal Transfusion in 2006 (Mintz et al. Transfusion 2006;46:1693-1704). INTERCEPT plasma is currently approved in Europe for use in all indications of plasma for transfusion, including treatment of TTP.
ABOUT BLOOD SYSTEMSFounded in 1943 as the Salt River Valley Blood Bank in Phoenix, Arizona, Blood Systems is one of the nation’s oldest and largest blood service providers. The Company’s non-profit community blood centers, United Blood Services, Blood Centers of the Pacific and Inland Northwest Blood Center, provide blood, blood components and special services to patients in more than 500 hospitals in 18 states. Its Creative Testing Solutions unit specializes in high volume blood donor testing and infectious disease reference work. Blood Systems also focuses on transfusion medicine research within its Blood Systems Research Institute, as well as the distribution of therapeutic biologicals and recombinant coagulation factors via its BioCARE division. Blood Systems Laboratories specializes in immunohematology, functioning as the major reference laboratory for transfusion-related compatibility issues for blood centers and hospitals in various parts of the country. http://www.bloodsystems.org/ ABOUT THE AMERICAN RED CROSS The American Red Cross shelters, feeds and provides emotional support to victims of disasters, supplies more than 40 percent of the nation's blood, teaches skills that save lives, provides international humanitarian aid, and supports military members and their families. The Red Cross is a not-for-profit organization that depends on volunteers and the generosity of the American public to perform its mission. For more information, please visit redcross.org or join our blog at http://blog.redcross.org. ABOUT CERUS Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.